BusinessMelinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare ConferenceBy Nasdaq OMXMar 14, 2018, 12:01 PM UTC
BusinessMelinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement WeatherBy Nasdaq OMXMar 13, 2018, 8:35 PM UTC
BusinessMelinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial ResultsBy Nasdaq OMXMar 13, 2018, 11:01 AM UTC
BusinessMelinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in EuropeBy Nasdaq OMXMar 8, 2018, 12:01 PM UTC
BusinessMelinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care ConferenceBy Nasdaq OMXMar 2, 2018, 12:00 PM UTC
BusinessMelinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018By Nasdaq OMXFeb 28, 2018, 12:01 PM UTC
BusinessMelinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTIBy Nasdaq OMXFeb 27, 2018, 9:05 PM UTC
BusinessMelinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in ArgentinaBy Nasdaq OMXFeb 20, 2018, 12:01 PM UTC
